<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03907540</url>
  </required_header>
  <id_info>
    <org_study_id>KD025-108</org_study_id>
    <secondary_id>2018-004773-28</secondary_id>
    <nct_id>NCT03907540</nct_id>
  </id_info>
  <brief_title>Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025</brief_title>
  <acronym>KD025-108</acronym>
  <official_title>Open-label, Two-part Study Designated to Assess the Absolute Bioavailability of KD025 and to Determine the Mass Balance Recovery, Metabolite Profile and Identification of Metabolite Structures for [14C]-KD025 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human, absorption, metabolism and excretion study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, two-part study designed to assess the absolute bioavailability of KD025 and to
      determine the mass balance recovery, metabolite profile and identification of metabolite
      structures for [14C]-KD025 in healthy male subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2019</start_date>
  <completion_date type="Actual">May 20, 2019</completion_date>
  <primary_completion_date type="Actual">May 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single centre, non-randomised, open-label, two-part study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute bioavailability (F) of KD025</measure>
    <time_frame>Pre-dose up to Day 3 post-dose</time_frame>
    <description>ratio of dose-adjusted area under the plasma concentration-time curve (following oral administration) to dose-adjusted area under the plasma concentration-time curve (following IV infusion)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in urine and feces</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total radioactivity (to administered radioactive dose) in urine and feces</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative total radioactivity in urine and feces</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profiling and structural identification in plasma</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
    <description>Number of metabolites &gt;10% of circulating radioactivity in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profiling and structural identification in urine</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
    <description>Number of metabolites &gt;10% of circulating radioactivity in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profiling and structural identification in feces</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
    <description>Number of metabolites &gt;10% of circulating radioactivity in feces</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of total [14C] radioactivity (KD025 and metabolites) following oral administration</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total [14C] radioactivity (KD025 and metabolites) following oral administration</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of total [14C] radioactivity (KD025 and metabolites) following oral administration</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to last measurable concentration (AUC0-t) of total radioactivity [14C] (KD025 and metabolites) following oral administration</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during terminal phase (Vz/F) of [14C]-KD025 following oral administration</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (Cl/F) of [14C]-KD025 following oral administration</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of [14C]-KD025 following IV infusion</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of [14C]-KD025 following IV infusion</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of [14C]-KD025 following IV infusion</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to last measurable concentration (AUC0-t) of [14C]-KD025 following IV infusion</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during terminal phase (Vz) of [14C]-KD025 following IV infusion</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (Cl) of [14C]-KD025 following IV infusion</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant change from baseline in vital signs, laboratory parameters, and electrocardiogram findings</measure>
    <time_frame>Pre-dose up to Day 15 post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part 1, Treatment A - KD025 Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KD025 Tablet, 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Treatment B - [14C]-KD025 solution for infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14C]-KD025 solution for infusion, 20 μg/mL (100 μg in 5mL), containing NMT 37 kBq (1000 nCi) [14C], as a 15 min IV infusion, 100 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Treatment C - [14C]-KD025 capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14C]-KD025 capsule, containing NMT 9.8 MBq (215 μCi) 14C, 200 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KD025</intervention_name>
    <description>KD025 tablet 200 mg, development candidate</description>
    <arm_group_label>Part 1, Treatment A - KD025 Tablet</arm_group_label>
    <other_name>SLx-2119</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-KD025 solution for infusion, 20 μg/mL</intervention_name>
    <description>test investigational medicinal product</description>
    <arm_group_label>Part 1, Treatment B - [14C]-KD025 solution for infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-KD025 capsule, 200mg</intervention_name>
    <description>test investigational medicinal product</description>
    <arm_group_label>Part 2, Treatment C - [14C]-KD025 capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males

          2. Good state of health (mentally and physically) as indicated by a comprehensive
             clinical assessment (detailed medical history and a complete physical examination),
             ECG and laboratory investigations (haematology, clinical chemistry and urinalysis)

          3. Body weight ≥50 kg

          4. Body mass index (BMI) of 18.0 to 35.0 kg/m2

          5. Must be willing and able to communicate and participate in the whole study

          6. Must have regular bowel movements (ie, average stool production of ≥1 and ≤3 stools
             per day)

          7. Subjects must have participated in Part 1 in order to be eligible for Part 2

          8. Must provide written informed consent

          9. Must agree to adhere to the contraception requirements of the study

        Exclusion Criteria:

          1. Subjects who previously participated in any other investigational study drug trial in
             which receipt of an investigational study drug occurred within 90 days prior to dosing

          2. Subjects who have previously participated in a study where subjects were dosed with
             KD025 (QSC200311 and QCL117415).

          3. Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee

          4. Subjects with pregnant partners

          5. History of any drug or alcohol abuse in the past 2 years

          6. Regular alcohol consumption in males &gt;21 units per week (1 unit = ½ pint beer, or a 25
             mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type)

          7. Current smokers and those who have smoked within the last 12 months. A breath carbon
             monoxide reading of greater than 10 ppm at screening and admission

          8. Current users of e-cigarettes and nicotine replacement products and those who have
             used these products within the last 12 months

          9. Radiation exposure, including that from the present study, excluding background
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,
             as defined in the Ionizing Radiation Regulations 2017, shall participate in the study.

         10. Subjects who have been enrolled in an ADME/IV microtracer study in the last 12 months

         11. Subjects who do not have suitable veins for multiple venepunctures/cannulation

         12. Clinically significant abnormal biochemistry, haematology or urinalysis. Subjects with
             blood platelet count, haemoglobin and red blood cells lower than the reference range
             will be excluded

         13. Confirmed positive drugs of abuse test result

         14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

         15. Evidence of renal impairment at screening

         16. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory
             or GI disease, neurological or psychiatric disorder

         17. Subject has a history or presence of any of the following:

               -  Active GI disease requiring therapy

               -  Hepatic disease and/or ALT or AST &gt; ULN

               -  Renal disease and/or serum creatinine &gt; ULN

               -  Other condition known to interfere with the absorption, distribution, metabolism
                  or excretion of drugs

         18. Subject has QT interval corrected using Fridericia's formula (QTcF) intervals &gt;450
             msec at screening or admission

         19. Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients

         20. Presence or history of clinically significant allergy requiring treatment

         21. Donation or loss of greater than 400 mL of blood within the previous 3 months

         22. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or
             herbal remedies in the 14 days before study drug administration.

        23 Failure to satisfy the investigator of fitness to participate for any other reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy males</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Sciences Ltd</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>absorption</keyword>
  <keyword>metabolism</keyword>
  <keyword>excretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

